My next write-up was going to be on $GSI.V, but unfortunately, the stock has more than doubled. Solution: I’ll soon introduce a new one-pager format for ideas with near-term catalysts. Same deep research process, just faster delivery. Re the name, it was experiencing an

No job hunting yet, so I built a virtual trading floor

An introduction to Hydreight Technologies $NURS.V $HYDTF on YouTube talking about the potential huge rewards, but also the risk youtu.be/hK-KxQP2A4c

Catalyst Watch is now fully comprehensive, tracking all press releases, 8-K filings, earnings reports, and call transcripts across North America. It’s already 70+ pages. Two must-bookmark resources that make my life much easier: • For tracking press releases:

The Outsider’s Checklist: A Practical Framework for Operators by William Thorndike

New write-up. New format. One-pagers now reserved for setups with near-term catalysts. Same deep research process, just faster delivery. A relevant quote from a John Rotonti Jr interview with Win Murray of Diamond Hill: "The outstanding [analysts] do a wonderful job of isolating the

Putting your investment philosophy and process down on paper is such a useful exercise. It frees up so much mental space. Hoping to finally share mine in the next few weeks. FWIW, the last write-up, where sales deceleration is about to turn into triple-digit growth over the next

Yday, $NURS.V agreed to acquire an initial 5% stake in Perfect Scripts in exchange for 2.25mm shares. As part of the agreement, they will partner to launch a 503B pharmacy, and Hydreight will receive the lowest pricing on all products sold or made available by Perfect Scripts.

$NURS.V - The Perfect Scripts Deal - Explained Shareholder webinar scheduled for July 24: hydreight.zoom.us/webinar/regist…

The Anatomy of the Perfect Investment Workstation • ThinkPad X1 Carbon • 3× Dell UltraSharp 27" 4K Monitors • ThinkPad TrackPoint Keyboard II • ThinkPad Bluetooth Silent Mouse • ThinkPad X1 ANC Headphones • Herman Miller Aeron Chair • Herman Miller Sit-to-Stand Desk •

Q2 Performance Review (+36.0%) is finally out! This update places all past write-ups in their current context, winners and losers alike. Several picks are being closed effective immediately, with three mistakes documented and lessons learned. Most names, though, have played out

$CURI Reports 53% Year-Over-Year Revenue Increase to $19 Million for Q2 2025

$NURS.V is now at ATHs and almost double from when first pitched in May. Back then, I wrote: "I’m not just projecting this to be my new multibagger. I’m absolutely sure it will be." From the moment I hit publish, I regretted being so definite. Confidence is important, but so is

Not necessarily surprises, but interesting at first glance. 20 of them, out of ~50 flagged on Byron Street. No DD on any, just sharing notes. 1. Acorn Energy, Inc. (ACFN) | Scientific & Technical Instruments Announced 2Q25 revenue of $3.5mm, up 55% yoy, and diluted EPS of $0.28

Nice to see many of our contributor pitches sitting on the 12 month new high list: $CLPT $NURS.V $LRGR $PNG.V $THEON.AS Thank you: Dakota [ Charles Hutchison Liger Cub (Byron Street Research) matt ] Todd Schuh Deep Sail Capital Jason Hirschman + $MDXH $LEU

Fintwin is an incredibly powerful community, if you know how to use it. I wanted to share how collaborative research on the platform helped me and many of my subscribers make real money on $NURS.V. Back in April, I got a DM from matt: "You should check Hydreight."